Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

被引:8
作者
Ma, Xiaohong [1 ,2 ]
Ma, Rong [3 ]
Zhang, Mengzhe [3 ]
Qian, Baicheng [1 ]
Wang, Baoliang [1 ]
Yang, Weijing [3 ]
机构
[1] Henan Univ Chinese Med, Affiliated Hosp 1, Dept Neurosci, Zhengzhou 450000, Peoples R China
[2] Henan Univ Chinese Med, Clin Med Sch 1, Zhengzhou 450046, Peoples R China
[3] Zhengzhou Univ, Sch Pharmaceut Sci, Henan Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
multiple sclerosis; immunotherapy; T cells; B cells; innate immune cells; REGULATORY T-CELLS; PLACEBO-CONTROLLED TRIAL; MYELIN BASIC-PROTEIN; GLATIRAMER ACETATE; B-CELLS; DENDRITIC CELLS; DOUBLE-BLIND; IFN-BETA; MENINGEAL INFLAMMATION; NEUROMYELITIS-OPTICA;
D O I
10.3390/pharmaceutics15030728
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the central nervous system. The main pathological features are inflammatory reaction, demyelination, axonal disintegration, reactive gliosis, etc. The etiology and pathogenesis of the disease have not been clarified. The initial studies believed that T cell-mediated cellular immunity is the key to the pathogenesis of MS. In recent years, more and more evidence has shown that B cells and their mediated humoral immune and innate immune cells (such as microglia, dendritic cells, macrophages, etc.) also play an important role in the pathogenesis of MS. This article mainly reviews the research progress of MS by targeting different immune cells and analyzes the action pathways of drugs. The types and mechanisms of immune cells related to the pathogenesis are introduced in detail, and the mechanisms of drugs targeting different immune cells are discussed in depth. This article aims to clarify the pathogenesis and immunotherapy pathway of MS, hoping to find new targets and strategies for the development of therapeutic drugs for MS.
引用
收藏
页数:20
相关论文
共 189 条
  • [21] Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS
    Chen, M
    Gran, B
    Costello, K
    Johnson, K
    Martin, R
    Dhib-Jalbut, S
    [J]. MULTIPLE SCLEROSIS, 2001, 7 (04): : 209 - 219
  • [22] IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis
    Chen, Meiyue
    Chen, Guangjie
    Deng, Shaohua
    Liu, Xin
    Hutton, George J.
    Hong, Jian
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2012, 242 (1-2) : 39 - 46
  • [23] Development of thymic Foxp3+ regulatory T cells: TGF-β matters
    Chen, WanJun
    Konkel, Joanne E.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2015, 45 (04) : 958 - 965
  • [24] Rituximab for the treatment of multiple sclerosis: a review
    Chisari, Clara Grazia
    Sgarlata, Eleonora
    Arena, Sebastiano
    Toscano, Simona
    Luca, Maria
    Patti, Francesco
    [J]. JOURNAL OF NEUROLOGY, 2022, 269 (01) : 159 - 183
  • [25] Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis
    Choi, Sung R.
    Howell, Owain W.
    Carassiti, Daniele
    Magliozzi, Roberta
    Gveric, Djordje
    Muraro, Paolo A.
    Nicholas, Richard
    Roncaroli, Federico
    Reynolds, Richard
    [J]. BRAIN, 2012, 135 : 2925 - 2937
  • [26] The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis
    Chu, Fengna
    Shi, Mingchao
    Zheng, Chao
    Shen, Donghui
    Zhu, Jie
    Zheng, Xiangyu
    Cui, Li
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2018, 318 : 1 - 7
  • [27] Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis
    Church, Molly E.
    Ceja, Guadalupe
    McGeehan, Megan
    Miller, Miles C.
    Farias, Priscilla
    Sanchez, Melissa D.
    Swain, Gary P.
    Assenmacher, Charles-Antoine
    Stopa, Edward G.
    Vite, Charles H.
    Bar-Or, Amit
    Alvarez, Jorge, I
    [J]. JOURNAL OF IMMUNOLOGY, 2021, 207 (01) : 44 - 54
  • [28] Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
    Cohan, Stanley L.
    Hendin, Barry A.
    Reder, Anthony T.
    Smoot, Kyle
    Avila, Robin
    Mendoza, Jason P.
    Weinstock-Guttman, Bianca
    [J]. CNS DRUGS, 2021, 35 (07) : 743 - 767
  • [29] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
    Cohen, Jeffrey A.
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Khatri, Bhupendra O.
    Montalban, Xavier
    Pelletier, Jean
    Capra, Ruggero
    Gallo, Paolo
    Izquierdo, Guillermo
    Tiel-Wilck, Klaus
    de Vera, Ana
    Jin, James
    Stites, Tracy
    Wu, Stacy
    Aradhye, Shreeram
    Kappos, Ludwig
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) : 402 - 415
  • [30] Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
    Confavreux, Christian
    O'Connor, Paul
    Comi, Giancarlo
    Freedman, Mark S.
    Miller, Aaron E.
    Olsson, Tomas P.
    Wolinsky, Jerry S.
    Bagulho, Teresa
    Delhay, Jean-Luc
    Dukovic, Deborah
    Truffinet, Philippe
    Kappos, Ludwig
    [J]. LANCET NEUROLOGY, 2014, 13 (03) : 247 - 256